牙周牙标记预测糖尿病患者的血糖控制10年后期分析
Salah M Ibrahim1, Munir Nasr Hamed2, Ansam Mahdi Khalel3
1Department of Oral Surgery, College of Dentistry, Kufa University, Najaf, Iraq. salahm.abrahem@uokufa.edu.iq.
Scientific reports
|October 17, 2025
概括
牙周健康影响糖尿病管理. 关键标志物,如探针上的出血和深口袋与HbA1c相关,有助于糖尿病患者的血糖控制评估.
科学领域:
- 口腔健康和内分泌学
- 临床牙周科 临床牙周科
- 糖尿病管理 糖尿病管理
背景情况:
- 糖尿病和牙周炎之间的双向关系构成了重大的公共卫生挑战.
- 有效管理糖尿病需要了解它对牙周健康的影响,反之亦然.
研究的目的:
- 评估糖尿病患者临床牙周参数与血糖控制 (HbA1c) 之间的关联.
- 开发和验证一个用于估计HbA1c的预测模型,使用可访问的牙周标记.
主要方法:
- 350名糖尿病患者10年 (2014-2023) 的回顾性队列研究.
- 数据提取包括人口统计,吸烟状况,HbA1c和牙周指数 (BOP%,PD≥5mm的位点%,牙缺失).
- 多变量线性回归和内部验证 (70%培训,30%测试) 用于构建和测试预测模型.
主要成果:
- HbA1c与PD≥5mm (r=0.38) 的%位点,BOP% (r=0.35) 和缺失牙 (r=0.30) (p<0.001) 显示出显著的相关性.
- 预测模型解释了训练组中的27.5%的HbA1c变异 (调整后R2=0.275),并在测试组中实现了R2=0.26.
- 该模型显示平均绝对误差 (MAE) 为1.02%的HbA1c.
结论:
- 特定的牙周标记与糖尿病患者的HbA1c水平显著相关.
- 开发的模型提供了一种经过验证的,非侵入性的工具,用于对糖尿病的血糖控制的椅子边风险分层.
- 这种方法可以帮助早期识别血糖控制不良的患者,促进及时的医疗转诊.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
Diabetes: Management and Pharmacotherapy
861
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
861


